Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 86 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06325696RecruitingPhase 2
H01 for adults with lung scarring (SOLIS study)
This study tests an oral medication (H01/hymecromone) to see if it can help people with progressive lung scarring (ILD). It lasts about 12 to 24 weeks and requires good lung function without needing oxygen at rest.
Research Triangle Park, North CarolinaAges 18–100 - NCT06267183RecruitingEarly Phase 1
Safety study of a new drug in healthy volunteers
This study tests a new investigational drug called SV001 in healthy volunteers to see if it is safe and how the body handles it. It is a first-in-human trial, meaning this drug has not been tested in people before.
ShanghaiAges 18–45 - NCT05988463RecruitingPhase 1
Study of artesunate for people with idiopathic pulmonary fibrosis
This study tests artesunate, a medicine that may help treat idiopathic pulmonary fibrosis (IPF), a condition that causes lung scarring. It is for people who are already taking other IPF treatments and want to see if adding artesunate can improve their condition.
Stanford, CaliforniaAges 40 years+ - NCT05190211Recruiting
Video exercise therapy for idiopathic pulmonary fibrosis
This study tests whether telerehabilitation (supervised exercise/therapy by video or remote tools) can help people with idiopathic pulmonary fibrosis (IPF) improve breathing and function. You may be able to take part if your condition has been stable and you haven’t recently done a pulmonary rehab program.
Istanbul, ZeytinburnuAges 18–75 - NCT03500731RecruitingPhase 1/Phase 2
Lung and bone marrow transplant for lung and blood failure
This Phase 1/2 study tests a special lung-and-bone-marrow transplant approach for people with severe lung disease and bone marrow failure (low blood counts). The goal is to see if the treatment is safe and whether it can improve outcomes when standard long-term immune-suppressing medicines are a poor fit.
Pittsburgh, PennsylvaniaAges 18–60 - NCT03800017Recruiting
Muscle strength and exercise function in lung scarring
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
Vancouver, British ColumbiaAges 40–80 - NCT00470327Recruiting
Study of how interstitial lung disease naturally changes
This study looks at how interstitial lung disease (lung scarring) typically progresses over time. It may help researchers understand what to expect and what changes to watch for.
Chicago, IllinoisAges 18 years+ - NCT07457463Recruiting
Pulmonary fibrosis self-management program
This study tests a learning and self-management program for people with pulmonary fibrosis. It helps you better understand and manage your lung condition.
BernAges 18 years+ - NCT07236541Recruiting
Mucus plugs and lung scarring in COPD patients having lung cancer surgery
This study looks at whether mucus plugs (thick mucus blocking the airways) in people with COPD might lead to more lung scarring after lung cancer surgery. It compares lung tissue from people with COPD to those with normal lungs.
ShanghaiAges 18–89 - NCT05895409Recruiting
Study risk factors in progressive lung scarring
This study looks at what factors contribute to worsening lung scarring seen on scans in people with certain lung diseases. Results may help doctors better understand and predict who will worsen over time.
Jinan, ShandongAges 18–80 - NCT05139719RecruitingPhase 2
HEC585 trial for slowing lung scarring decline
This Phase 2 study tests whether HEC585 can slow the decline in lung function in people with progressive fibrosing interstitial lung disease (PF-ILD). It may help preserve breathing capacity and breathing tolerance over time.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06940427RecruitingPhase 2
Testing a new PET scan for lung scarring
This trial is testing a new type of PET scan (FAPI PET) to help doctors see if lung scarring (fibrosis) is getting worse or getting better. It may help decide if a treatment change is needed.
Madison, WisconsinAges 18 years+ - NCT07816185RecruitingPhase 3
Inhaled study drug for pulmonary hypertension with lung scarring
This study tests an inhaled medication called mosliciguat for people with pulmonary hypertension (high blood pressure in the lungs) caused by certain types of lung scarring. It may help improve your ability to exercise and manage symptoms.
Kissimmee, FloridaAges 18–85 - NCT07333183RecruitingPhase 2
Mosliciguat plus treprostinil for lung disease with pulmonary hypertension
This trial tests a new medicine called mosliciguat combined with an inhaled treatment (treprostinil) for people who have both scarring lung disease (interstitial lung disease) and high blood pressure in the lungs. It aims to see if this combination can improve how well you feel and function.
Santa Barbara, CaliforniaAges 18–85
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 86 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.